WHAT IS ESKETAMINE?
Esketamine, the molecule found in ketamine. Studies have shown that Esketamine is more
potent that ketamine.Because it’s more potent, it can be used at a lower dose and may have
fewer side effects. While other antidepressants modulate a group of chemicals in the brain
called monoamines, esketamine targets glutamate,which is found to be in abundance in the
brains of people with depression.
WHAT IS ESKETAMINE?
Esketamine, the molecule found in ketamine. Studies have shown that Esketamine is more potent that ketamine. Because it’s more potent, it can be used at a lower dose and may have
fewer side effects. While other antidepressants modulate a group of chemicals in the brain
called monoamines, esketamine targets glutamate,which is found to be in abundance in the brains of people with depression.
IS INTRANASAL SPRAVATO THE ONLY WAY TO DELIVER SPRAVATO FOR TREATMENT
RESISTANT DEPRESSION?
SPRAVATO is only administered intranasal. Unfortunately, the effectiveness and predictability of response and the overwhelming majority of scientific studies of SPRAVATO for depression and mental health conditions have been performed using intranasal SPRAVATO. In short, intranasal SPRAVATO is the gold standard route for SPRAVATO administration.
CAN SPRAVATO HELP ME?
Research over the last 5-10 years has shown that Intranasal administration of SPRAVATO in sub-anesthetic doses remarkably benefits 70% of people suffering from severe depression. While the benefits can truly be remarkable, they often occur in ways that differ from some patients’ expectations.
That is, the changes produced by -SPRAVATO can be subtle, and while they occur quickly, they do not always manifest themselves immediately. This phenomenon stands in contrast to some patients’ expectations ofa benevolent “thunderbolt” response from SPRAVATO treatment. With this in mind, we will work closely with you to identify and evaluatethe benefits of SPRAVATO as a depression medication.
HOW MANY INTRANASAL ADMINISTRATIONS DO I NEED?
The standard SPRAVATO protocol for depression that has resulted from scientific trials and clinical experience around the U.S. is about 2 times per week for the first 4 weeks, and then weekly for 2-4weeks and then maintenance (usually once every 2 weeks). It has been shown that serial Intranasal administrations are more effective than single Intranasal administrations,
and many patients who respond to SPRAVATO treatment require maintenance Intranasal administrations on an ongoing basis following the initial series.
and many patients who respond to SPRAVATO treatment require maintenance Intranasal administrations on an ongoing basis following the initial series.
The frequency of these maintenance Intranasal administrations varies greatly from person to person. It is important to note that SPRAVATO Intranasal administrations should not be viewed as a cure for depression, but rather a depression treatment that is a piece of a multi-modal approach that may include ongoing mental health therapy or other depression medication.
CAN I CONTINUE TO TAKE MY REGULAR MEDICATIONS?
Yes, you should not stop your antidepressant medications in order to receive SPRAVATO. It is essential that we review your current medication list prior to beginning SPRAVATO treatments.
HOW SOON CAN MY PATIENTS DRIVE AFTER TAKING SPRAVATO?
Caution patients that SPRAVATO™ may impair their ability to drive or operate machinery. Instruct patients not to engage in potentially hazardous activities requiring complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.
